Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 27 systematic review(s)/meta-analysis(es). ^[1-27]
• Healing of Erosive Esophagitis (EE): Vonoprazan 20 mg was superior to lansoprazole 30 mg in healing severe EE (Los Angeles Grade C/D) at weeks 2, 4, and 8. Vonoprazan 10 mg and 20 mg also showed better maintenance of healed EE compared to lansoprazole 15 mg at week 24.
• GERD Symptom Relief: Vonoprazan provided higher rates of heartburn symptom resolution compared to PPIs, with significant improvements by Day 7.
• H. pylori Eradication: Vonoprazan-amoxicillin dual therapy showed comparable efficacy to vonoprazan-amoxicillin-clarithromycin triple therapy and superior efficacy to PPI-based triple therapy, particularly with vonoprazan-based regimens being more effective overall.
• PPI-Resistant GERD: Vonoprazan demonstrated high efficacy in healing and maintaining PPI-resistant EE and moderate efficacy in improving GERD symptom scores.
• There were no significant differences in the rate of adverse events (AEs) and serious adverse events (SAEs) between vonoprazan and PPIs.
• Vonoprazan 20 mg had a higher incidence of treatment-emergent adverse events (TEAEs) compared to lansoprazole 15 mg, but not compared to vonoprazan 10 mg.
• Long-term use of vonoprazan was associated with a higher incidence of adverse events compared to short-term use.
• There is no population types or subgroups information available in the reviewed documents.